Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis

Author(s): Teodoro J. Oscanoa*, José Amado, Xavier Vidal, Roman Romero-Ortuno

Journal Name: Current Reviews in Clinical and Experimental Pharmacology
(Formerly Current Clinical Pharmacology)

Volume 16 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Anti-hypertensive medications may reduce the incidence of cognitive disorders. This may be due to reasons beyond their pure hypotensive effect. This study aimed to systematically review the association between the use of Angiotensin-Receptor Blockers (ARBs) and the incidence of Alzheimer’s disease (AD).

Methods: We systematically searched studies reporting the association between ARB use and the incidence of AD.

Results: Ten studies (1 RCT, 2 case-control and 7 cohort studies) met the inclusion criteria. When all observational studies (9) were analyzed, ARB use was associated with a reduced risk of incident AD (HR 0.72, 95% CI: 0.58-0.88, p<0.001). In the only RCT, decrease in the incidence of AD was also significant (HR= 0.31, 95% CI: 0.14-0.68).

Conclusion: ARB use may reduce the risk of incident AD. This association does not imply causation and further research is required to clarify potential mechanisms.

Keywords: Angiotensin-receptor blockers, alzheimer´s disease, elderly, angiotensin II, meta-analysis, pro-oxidant effects.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2021
Published on: 29 April, 2021
Page: [73 - 78]
Pages: 6
DOI: 10.2174/1574884715666200131120224
Price: $65

Article Metrics

PDF: 8